• Journal of Plant Biotechnology
• /
• 제43권3호
• /
• pp.391-396
• /
• 2016

본 연구는 Apple stem grooving virus (ASGV)에 감염된 배 (Pyrus pyrifolia L.) '만수'의 기내배양 식물체를 이용하여 효과적인 배 바이러스 무병화 기술을 알아보고자 수행하였다. 식물체의 경정조직을 잘라 열처리($37^{\circ}C$), 한냉처리($4^{\circ}C$), 항바이러스제인 ribavirin을 단독 또는 복합처리하였다. 처리기간은 2, 4, 8주였으며 ribavirin 농도는 20과 $40mg{\cdot}L^{-1}$이었다. 바이러스 제거율은 Reverse transcription polymerase chain reaction 분석으로 확인하였다. 신초 생존율은 2주간 한냉처리, 항바이러스제 단독처리와 한냉처리와 항바이러스제가 복합처리된 그룹에서 100%로 높았고 열처리에서 33.3%로 가장 낮았다. 단독으로 ribavirin을 처리한 그룹은 처리기간이 길수록 신초 생존율이 감소하는 경향이었다. ASGV 제거율은 2주간 ribavirin $40mg{\cdot}L^{-1}$ 농도로 처리한 그룹과 열처리와 ribavirin을 복합처리한 그룹에서 100%로 높았다. 한냉처리한 그룹의 바이러스 제거율은 16.7%로 가장 낮았으나 한냉처리와 ribavirin을 복합처리한 그룹에서는 43.3%로 향상되었다. 모든 처리에서 처리기간이 길수록 바이러스 제거율은 증가하였다. 본 실험을 통해 배 ASGV 제거에는 경정배양과 더불어 항바이러스제인 ribavirin을 $20mg{\cdot}L^{-1}$ 농도로 4주간 처리하거나 $40mg{\cdot}L^{-1}$ 농도로 2주간 단독처리만으로도 효과적으로 무병화가 가능할 것으로 판단되었다.

• 대한수의학회지
• /
• 제25권1호
• /
• pp.7-17
• /
• 1985

Many investigators have been pursuing various attempts so far to produce hepatitis B surface antigen(HBsAg) vaccines using the techniques such as isolation from plasma of chronic HBsAg carrier, recombinant DNA technique or preparation of synthetic peptides specific for immunogenic determinants. Hepatitis B virus can not grow on any cell lines by the tissue culture technique at the present time. The plasma of chronic HBsAg carrier is expensive and its source is limited. The HBsAg from the recombinant DNA technique gave still very low yield. Another approach, therefore, has been initiated to develop a synthetic hepatitis B virus vaccine. The possible use of several distinct synthetic vaccines in prophylaxis can be facilitated by availability of full synthetic immunogens. Peptides synthesized for potential application as antiviral vaccines have been mostly tested in the form of conjugates with carrier proteins, although the free synthetic peptide can be immunogenic. To understand basic knowledges on the antigenicity and immunogenicity of a synthetic peptide specific for major immunogenic determinant of HBsAg, a nonapeptide, $H_2N^{139}Cys-Thr-Lys-Pro-Thr-Asp-Gly-^{146}Asn-Aba$ COOH, which corresponds to HBsAg amino acid residues 139 to 147, was synthesized by the Merrifield's solid-phase method with a slight modification. The antigenicity and immunogenicity of this specific synthetic peptide were examined comparing with purified plasma-derived natural HBsAg. The results obtained are as follows; 1. The peptide synthesized showed the identical amino acid composition to the theoretical value. The degree of purification and molecular weight were acertained by methods of high performance liquid chromatography and mass spectrometry. 2. Using m-maleimidobenzoyl-N-hydroxysuccinimide ester as a conjugating agent, the synthetic peptide was conjugated to rabbit albumin and ${\gamma}$-globulin, tetanus and diphtheria toxoids, and keyhole limpet hemocyanin. Their conjugation yields were 8.3, 9.5, 15.8, 13.5, and 11.2%, respectively. 3. The natural HBsAg was purified from plasma of chronic HBsAg carrier. By the electron microscopic observation of the purified natural HBsAg preparation, no Dane particles were observed and the preparation showed negative DNA polymerase activity. 4. Antigenicity of the synthetic peptide and the plasma-derived natural HBsAg was determined by competition radioimmunoassay using $^{125}I$-natural HBsAg. Their 50% inhibitions appeared as $90{\mu}g/ml$ and $0.12{\mu}g/ml$ for the synthetic peptide and the natural HBsAg, respectively. This indicates that the former was about 750-fold less antigenic than the latter. 5. Immunogenicity of the synthetic peptide was determined by administering the peptide-carrier conjugates into rabbits with and without Freund's complete adjuvant. Regardless the carrier proteins and adjuvant, positive immune responses to the synthetic peptide were observed. The higher antibody titers, however, were shown in the groups administered with Freund's complete adjuvant. 6. Immunizing dose 50% in mice of the various peptide-carrier conjugates was 5.47, 6.00, 65.16, 31.25 and $13.03{\mu}g/dose$ for rabbit albumin and ${\gamma}$-globulin, tetanus and diphtheria toxoids, and keyhole limpet hemocyanin, respectively, while the natural HBsAg showed $0.65{\mu}g/dose$. 7. It was postulated that homologous proteins prefer to heterologous ones as the carriers.

• 식물병연구
• /
• 제12권2호
• /
• pp.91-98
• /
• 2006

Acinetobacter sp. KTB3의 배양여과액으로 제조한 분말 제제 KNF2022의 바이러스 감염억제 효과를 PMMoV 와 N. glutinosa 또는 N. tabacum cv. Xanthi nc를 이용하여 검정한 결과, 증류수 1/100 배양액의 실질 농도 10,000 ppm) 희석농도에서 $94.3{\sim}95.6%$의 높은 감염억제 효과를 나타냈다. 이 1/100 희석농도를 이용하여 PepMoV-C amaranticolor에서 검정한 억제효과는 97.1%, CMV-C amaranticolor 에서는 92.5%의 감염억제를 나타냈다. KNF2022 희석액을 N. glutinosa의 반엽에 도말하고 일정 시간 경과 후 PMMoV를 접종하여 조사한 억제효과의 지속성은 처리 2 일 후까지 약 80% 선에서 억제효과를 나타냈으나, 처리 4 일 후부터는 50% 수준으로 저하되었다. 고추에 KNF2022를 처리한 후 3 종의 바이러스를 접종하고 발현되는 병징을 조사한 결과, 각 바이러스를 단독으로 접종하였을 경우는 바이러스의 종류에 관계없이 접종 후 10 일까지 병징발현이 지연되는 효과를 보였다. 특히 PepMoV를 접종한 경우는 접종 후 30 일까지 병징발현이 억제되어 제제의 처리효과가 뚜렷하게 나타났다. 한편 이들 3 종 바이러스의 복합감염에 대한 KNF2022의 효과는 모든 바이러스 조합에서 단독감염 보다 강하게 발현되어 병징억제의 효과는 뚜렷하게 나타나지 않았다. 제제를 처리한 고추에서 증식된 바이러스의 농도를 PCR 및 ELISA로 검출한 결과, PepMoV를 단독으로 접종한 경우, 접종 후 30 일까지 cDNA가 검출되지 않았다. RT-PCR 검정에서 억제효과가 인정된 PepMoV와 그 복합감염 의 조합에 대해서 ELISA 검정을 실시한 결과, PCR 검정에서 얻어진 결과와 유사한 패턴을 보여 PepMoV에 대한 감염억제효과가 뚜렷하게 인정되었다. KNF2022를 처리하여 전자현미경으로 관찰한 PMMoV와 PepMoV는 처리 5 분 후에 각각 200-250 nm 및 400-600 nm의 길이로 절단된 입자가 많이 관찰되었고, 처리 30 분 후에는 대부분 100-150nm와 300-500 nm의 절편입자로 관찰되었다. 이와 같이 절단된 입자가 증가할수록 N. tabacum cv. Xanthi nc 와 C. amaranticolor에서 나타난 병반수는 급격하게 감소되었다. 한편 KNF2022를 처리한 후 전자현미경을 관찰한 CMV의 바이러스 입자는 처리시간에 비례하여 파괴된 입자의 수가 증가하였으며, 파괴된 바이러스입자가 증가할수록 C. amaranticolor에서의 병반수도 감소되었다.

• 동의생리병리학회지
• /
• 제19권2호
• /
• pp.481-489
• /
• 2005

Lonicerae Flos has antibacterial effects against Staphylococcus aureus, streptococci, pneumococci, Bacillus dysenterii, Salmonella typhi, and paratyphoid. It is an antiviral agent. The herb has a cytoprotective effect against $CCl_{4}-induced$ hepatic injury. It has antilipemic action, interfering with lipid absorption from the gut. Nowadays this herb is used mainly in the treatment of upper respiratory infections, such as tonsillitis and acute laryngitis. It is also used in the treatment of skin suppurations, such as carbuncles, and to treat viral conjunctivitis, influenza, pneumonia, and mastitis. Lonicerae Flos is dried flower buds of Lonicera japonica, L. hypoglauca, L. confusa, or L. dasystyla. But, for the most part, we use whole plant of Lonicera japonica, as a flower bud of it. And, little is known of the original copy of effects of whole plant, except for the 'Bon-Cho-Gang-Mok', which is written the effects of flower of Lonicera japonica are equal to effects of leaves and branch of it. The present study was conducted to evaluate the effect of flower and whole plant of Lonicera japonica on the regulatory mechanism of cytokines, inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX-2) for the immunological activities in Raw 264.7 cells. In Raw 264.7 cells stimulated with lipopolysaccharide (LPS) to mimic inflammation, flower and whole plant of Lonicera japonica water extracts inhibited nitric oxide production in a dose-dependent manner and abrogated iNOS and COX-2. Flower and whole plant of Lonicera japonica water extract did not affect on cell viability. To investigate the mechanism by which flower and whole plant of Lonicera japonica water extract inhibits iNOS and COX-2 gene expression, we examined the on phosphorylation of inhibitor ${\kappa}B{\alpha}$ and assessed production of $TNF-{\alpha}$, $interleukin-1{\beta}$ $(IL-1{\beta})$ and interleukin-6 (IL-6). Results provided evidence that flower and whole plant of Lonicera japonica inhibited the production of $IL-1{\beta}$, IL-6 and activated the phosphorylation of inhibitor ${\kappa}B{\alpha}$ in Raw 264.7 cells activated with LPS. These findings suggest that flower and whole plant of Lonicera japonica can produce anti-inflammatory effect, which may play a role in adjunctive therapy in Gram-negative bacterial infections, respectively.